RxDoctor Payments Data

Lindsay Hayler, PA

Physician Assistant · Manchester, TNNPI 1053558023

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $28,090 of the $36,456 with a category attached, or 77.1%. Galderma Laboratories, L.p. accounts for 94.1% of it on its own, with 20 other manufacturers making up the rest. Reporting peaked in 2023 at $25,270 and has fallen 93.9% since, to $1,535 in 2025. Among physician assistant clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$36,456in general payments, 2019–2025

Across 168 payments — averaging $217.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Galderma Laboratories, L.p.$34K
  • Johnson & Johnson$493
  • Pfizer$255
  • AbbVie$222
  • Novartis$193
  • Incyte Corporation$160
  • plus $824 from 15 others

What the payments were for

  • Speaking & faculty fees$28,09077%
  • Travel & lodging$3,95111%
  • Food & beverage$3,97111%
  • Education$4441%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$36,456 in reported general payments places this provider in the 95th percentile of 2,404 physician assistant providers in Tennessee.

See all physician assistant providers in Tennessee

Medicare billing

Part B allowed, 2024
$278,642
Medicare patients
716
Services billed
6,872

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab26$100,460
Cosentyx (2 Syringes)Secukinumab12$86,575
Dupixent SyringeDupilumab13$47,594
Clobetasol Propionate136$10,859
Ketoconazole438$9,049
Fluorouracil47$3,958
Mupirocin396$3,388
Mometasone Furoate99$2,395
Triamcinolone Acetonide139$1,684
Acitretin13$1,572
Doxycycline Hyclate109$1,200
Clindamycin Phosphate26$1,198
Metronidazole15$773
ValacyclovirValacyclovir Hcl28$420
Cephalexin122$322

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisCosentyx (2 Syringes)$193$86,57512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,404 physician assistant providers in Tennessee.

Other physician assistant in Manchester

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →